Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Patients with type 1 and type 2 diabetes mellitus (T1D and T2D) have a higher incidence of heart failure (HF).
• This specific cardiac condition is termed diabetic cardiomyopathy (DCM).
• DCM pathogenesis is multifactorial, involving metabolic changes, microvascular disease, and structural alterations.

Purpose of the Study:

• To review the current understanding of diabetic cardiomyopathy (DCM).
• To evaluate the impact of hypoglycemic drugs on heart failure (HF) in diabetic patients.
• To identify potentially beneficial drug classes for managing HF in T2D.

Main Methods:

• Literature review of existing evidence on diabetic cardiomyopathy and HF treatments.
• Analysis of current scientific society recommendations for HF management in diabetes.
• Evaluation of the effects of various hypoglycemic agents on HF outcomes in T2D.

Main Results:

• Diabetic cardiomyopathy (DCM) is a significant complication in T1D and T2D patients.
• Current HF guidelines do not specifically differentiate treatment for diabetic patients.
• Sodium-glucose-co-transporter 2 inhibitors and metformin appear beneficial for T2D patients with HF.

Conclusions:

• Diabetic cardiomyopathy (DCM) necessitates careful consideration in diabetes management.
• Specific hypoglycemic agents, namely SGLT2 inhibitors and metformin, show potential benefits in managing HF in T2D.
• Further research may refine treatment strategies for HF in diabetic populations.